Intercept's liver disease drug proves highly effective in study
Primary biliary cirrhosis (PBC) is caused by autoimmune destruction of the ducts that transport bile acids out of the liver, resulting in toxic buildup of bile acids. The disease causes progressive liver damage and often leads to need for a liver ...
Reuters UK - Fri, 11 Apr 2014 22:03

Obeticholic Acid Shows Promise for Primary Biliary Cirrhosis
However, he pointed out, the study evaluated surrogate end points rather than hard clinical outcomes. Because primary biliary cirrhosis and other chronic liver diseases develop over many years or decades, surrogate markers must be relied on. Primary ...
Medscape - Tue, 15 Apr 2014 14:43

Obeticholic Acid Produces Meaningful Biochemical And Clinical Improvements ...
Results from an international Phase III study presented today at the International Liver CongressTM 2014 have shown obeticholic acid (OCA) given to patients suffering from Primary Biliary Cirrhosis (PBC) who previously had an inadequate response to, ...
RedOrbit - Mon, 14 Apr 2014 08:56

Late breaker: Obeticholic acid produced improvements in primary biliary ...
Healio - Sat, 12 Apr 2014 21:05

Intercept Pharma (ICPT) Issues Additional OCA Phase 3 POISE Data at EASL (subscription) - Mon, 14 Apr 2014 03:41

Positive Results on Intercept Pharma's OCA - Analyst Blog
NASDAQ - Mon, 14 Apr 2014 12:30

Intercept Reports Additional Positive Data From POISE Trial at EASL Late ...
Wall Street Journal - Sat, 12 Apr 2014 09:07

Daily Checkup: New approaches to treating liver problems in children
There are many pathways that can lead to pediatric liver disease and eventually liver failure. “Some children have congenital structural abnormalities like biliary atresia that interfere with their liver function and can eventually require a transplant ...
New York Daily News - Sat, 12 Apr 2014 23:00

City scientists trying to grow liver in lab
At the Institute of Liver and Biliary Sciences in New Delhi, the doctors have been using this technology to give a window period for liver failure patients on the wait for transplant. Not just that, using the concept of dialysis, the scientists here ...
Times of India - Tue, 15 Apr 2014 12:07

Liver disease drug effective in late stage trial
... obeticholic acid achieves its primary endpoint of reducing serum alkaline phosphatase, holding it to less than 1.67x the upper limit of normal and maintaining bilirubin within normal limits in a late-stage clinical trial for patients with primary ...
Seeking Alpha - Mon, 14 Apr 2014 04:37

Intercept grabs the spotlight at EASL, builds case for lead drug OCA
Investigators for Intercept Pharmaceuticals spelled out the impact of its lead therapy on rare cases of a liver disease called primary biliary cirrhosis (PBC), fleshing out the results of a late-stage study that it will use to seek U.S. and European ...
FierceBiotech - Sat, 12 Apr 2014 15:04

Albireo Lead Compound A4250 Shows Promise Against Liver Injury In Mice
Swedish biotechnology company Albireo announced that its lead compound A4250 for cholestatic liver disease was successful in protecting against bile acid-mediated cholestatic liver damage in mice. ... indicate that A4250 has beneficial effects on a ...
BioResearch Online (press release) - Mon, 14 Apr 2014 12:02

1  2  3  4  5  6  7  8    ->

Last update: April 2009